Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

By the numbers: Contract pharmacy participation in the 340B program

By Nicole Longo  |    March 31, 2022
There are many things that set the 340B program apart from other federal prescription drug programs, namely that patients are not the primary beneficiary. While in other programs, patients qualify...   Read More

Report: More than 600 medicines in development for diseases affecting women

By Lori Reilly  |    March 31, 2022
As we approach the end of celebrating Women’s History Month, we’re taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women’s health.   Read More

The patient experience: Uncovering the barriers to care for insured Americans

By Cynthia Hicks  |    March 28, 2022
Nearly half of insured Americans who take prescription medicines encounter affordability and access barriers to care, according to the findings of the newest installment of the Patient Experience...   Read More

Correcting the record: Putting medicine costs and spending in context

By Nicole Longo  |    March 24, 2022
Last week, the Senate Finance Committee held a hearing focused on drug prices where the discussion was filled with misleading claims. We agree too many Americans struggle to afford their medicines,...   Read More

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

By Andrew Powaleny  |    March 17, 2022
Today, the House Energy & Commerce Committee’s Subcommittee on Health will meet to discuss policy proposals to “encourage innovation and improve oversight” regarding medical innovation. This hearing...   Read More

Sharing rebates can save Americans with diabetes $500 each year and improve adherence, especially for Black and Hispanic Americans

By Katie Koziara  |    March 16, 2022
A new study by GlobalData looked at brand oral antidiabetic drugs (OADs) and found that sharing negotiated rebates with patients in commercial health plans at the pharmacy counter can help lower...   Read More

Biopharmaceutical industry drives economic growth in all 50 states

By Tim McClung  |    March 14, 2022
The innovative biopharmaceutical industry has long been a significant driver of the nation’s economic growth and a key contributor to state and regional economies. A new report from TEConomy Partners...   Read More

Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

By Guest Contributor  |    March 14, 2022
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

By Gabby Migliara  |    March 11, 2022
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...   Read More

If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?

By Brian Newell  |    March 8, 2022
Concerns about inflation continue to be top of mind for many Americans, as prices for basic services and necessities climb at a rapid pace. But there is one bright spot in this otherwise bleak...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates